En undersøgelse af JNJ-80948543 i kombination med andre CD3 T-celle-engagers hos deltagere med recidiverende/refraktær B-celle non-Hodgkin-lymfom (R/R B-celle NHL)
Et fase 1b-studie af JNJ-80948543 i kombination med andre CD3 T-celle-engagers (TCE'er) hos deltagere med recidiverende/refraktære B-celle non-Hodgkin lymfoide (R/R B-celle NHL) maligniteter
The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to further assess the safety of JNJ-80948543 at the RP2R in combination with JNJ-75348780 (Part 2: Dose Expansion).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Concord, Australien, 2139
- Concord Hospital
-
Fitzroy, Australien, 3065
- St Vincents Hospital Melbourne
-
North Ryde, Australien, 2109
- Macquarie University Hospital
-
-
-
-
-
Leicester, Det Forenede Kongerige, Le1 5ww
- University Hospitals Of Leicester Nhs Trust
-
-
-
-
-
Barcelona, Spanien, 08036
- Hosp. Clinic de Barcelona
-
Barcelona, Spanien, 08035
- Hosp Univ Vall D Hebron
-
L'Hospitalet de Llobregat, Spanien, 08908
- Inst. Cat. Doncologia-H Duran I Reynals
-
Madrid, Spanien, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Spanien, 28007
- Hosp. Gral. Univ. Gregorio Maranon
-
-
-
-
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologic documentation of diffuse large B-cell lymphoma (DLBCL), including high-grade B-cell lymphoma and DLBCL arising from indolent lymphoma. All participants must have received at least 2 prior lines of therapy
- Participants must have measurable disease as defined by the appropriate disease response criteria
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Hematologic laboratory parameters must meet the required criterias and the values must be without a transfusion or growth factors for at least 7 days prior to the first dose of study drug
- Participants of childbearing potential must have a negative highly sensitive serum pregnancy test (beta (β)-human chorionic gonadotropin) at screening and within 24 hours before the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study
Exclusion Criteria:
- Known active central nervous system involvement (CNS) or leptomeningeal involvement
- Prior solid-organ transplantation
- Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (example, methotrexate or tacrolimus) within 1 year prior to first dose of study drug
- Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, vitiligo, peripheral neuropathy, or endocrinopathies that are stable on hormone replacement, which may be Grade 2)
- Clinically significant pulmonary compromise defined as the need for supplemental oxygen to maintain adequate oxygenation
- Evidence of clinically significant and/or symptomatic infection (viral, bacterial, or fungal) at the time of study drug initiation. Anti-microbial treatment for infection must be discontinued at least 7 days before the first dose of study drug
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: JNJ-80948543
Participants will receive JNJ-80948543 in combination with JNJ-75348780 to determine the recommended phase 2 regimen (RP2R) in Part 1 (Dose escalation). JNJ-80948543 will be dosed in an escalation manner in combination with fixed doses of JNJ-75348780. In Part 2 (Dose expansion) participants will receive RP2R of JNJ-80948543 as determined in Part 1 in combination with JNJ-75348780. |
JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection. JNJ-75348780 will be administered as SC injection. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants with Dose-limiting Toxicity (DLT)
Tidsramme: Up to 1 year and 10 months
|
Number of participants with DLT will be reported. DLTs are defined as any of the treatment-related toxicities: any toxicity that would require discontinuation of treatment; Fatal toxicity; Non-hematologic toxicity (Grade 3 toxicity or higher with exceptions); and Hematologic Toxicity (Grade 4 neutrophil count decrease; Grade 4 febrile neutropenia; Grade 3 febrile neutropenia that does not recover with best supportive care within 7 days; Grade 4 platelet count decrease for >=7 days or Grade >3 with Grade >=2 bleeding; Grade 4 anemia). |
Up to 1 year and 10 months
|
|
Number of Participants with Adverse Events (AEs)
Tidsramme: Up to 1 year and 10 months
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to 1 year and 10 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum Concentration of JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months
|
Serum Concentration for JNJ-80948543 and JNJ-75348780 will be reported. |
Up to 1 year and 10 months
|
|
Area Under the Curve (AUCtau) for JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months
|
AUC tau is defined as area under the serum concentration-time curve during a dosing interval for JNJ-80948543 and JNJ-75348780. |
Up to 1 year and 10 months
|
|
Maximum Serum Concentration (Cmax) for JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months
|
Cmax for JNJ-80948543 and JNJ-75348780 will be reported. |
Up to 1 year and 10 months
|
|
Time to Reach Cmax (Tmax) for JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months
|
Tmax is the time to reach maximum observed serum concentration for JNJ-80948543 and JNJ-75348780. |
Up to 1 year and 10 months
|
|
Number of Participants with Presence of Anti-Drug Antibodies of JNJ-80948543 and JNJ-75348780
Tidsramme: Up to 1 year and 10 months
|
Number of participants with presence of anti-drug antibodies of JNJ-80948543 and JNJ-75348780 will be assessed. |
Up to 1 year and 10 months
|
|
Overall Response Rate (ORR)
Tidsramme: Up to 1 year and 10 months
|
ORR is defined as the percentage of participants who have a best response of partial response (PR) or better as assessed by the investigator based on standard response criteria. |
Up to 1 year and 10 months
|
|
Complete Response Rate (CRR)
Tidsramme: Up to 1 year and 10 months
|
CR is defined as the percentage of participants who achieve a best response of CR as assessed by the investigator based on standard response criteria. |
Up to 1 year and 10 months
|
|
Duration of Response (DoR)
Tidsramme: Up to 1 year and 10 months
|
DOR is defined as the time from the first efficacy evaluation at which the participant meet all criteria for a response of PR or better to the date of first documented evidence of progressive disease or death as assessed by the investigator based on standard response criteria. |
Up to 1 year and 10 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 80948543LYM1002
- 80948543LYM1002 (Anden identifikator: Janssen Research & Development, LLC)
- 2024-514176-41-00 (Registry Identifier: EUCT number)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .